Pasar al contenido principal

BIOMARKERS4CURE: BIOMARCADORES PREDICTIVOS DE RESPUESTA A COMBINACIONES DE INMUNOTERAPIA MAS QUIMIOTERAPIA NEOADYUVANTE EN PACIENTES CON CANCER DE PULMON OPERABLE

PI21/01500

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2021
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INVESTIGACION BIOMEDICA HOSPITAL PUERTA DE HIERRO
Centro realización INSTITUTO DE INVESTIGACION SANITARIA DEL HOSPITAL UNIV. PUERTA DE HIERRO MAJADAHONDA (IDIPHIM)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

  • Provencio Pulla, Mariano|||0000-0001-6315-7919
  • Nadal, Ernest|||0000-0002-9674-5554
  • González Larriba, José Luis|||0000-0003-2631-0309
  • Insa, Amelia|||0000-0002-3438-6170
  • Sánchez Hernández, Alfredo|||0000-0001-5826-8390
  • Del Rosario García-Campelo, María|||0000-0003-2113-1504
  • Rogado, J.
  • Martinez-Marti, Alex|||0000-0002-6714-9526
  • Bosch-Barrera, J.|||0000-0002-0893-7821
  • Bernabé, Reyes|||0000-0003-0312-9195
  • Ponce, S.
  • Reguart, Noemi|||0000-0001-8190-499X
  • Dómine Gómez, Manuel|||0000-0003-1634-9832
  • Aguilar, Alba
  • Majem Tarruella, Margarita|||0000-0002-9919-7485
  • Estival, Anna|||0000-0002-2788-9159
  • Cobo, Manuel|||0000-0003-3402-1144
  • Camps, Carlos|||0000-0002-0648-5403
  • Calvo, Virginia|||0000-0002-3503-4847
  • Collazo-Lorduy, Ana
  • Cruz-Bermúdez, Alberto|||0000-0001-5136-7011
  • Romero, A.
  • Robado de Lope, Lucía
  • Serna-Blasco, Roberto
  • Diz Taín, Pilar|||0000-0003-4284-3965
  • Massuti, Bartomeu|||0000-0002-6247-4493
  • Casal-Rubio, Joaquín
  • Sequero López, S.
  • Vázquez Estévez, S.
  • Castro, Javier de|||0000-0002-3622-6306
  • Coves Sarto, J.
  • Peña Cabia, Silvia
  • López Martín, A.
  • Sala González, María Ángeles
  • Barneto Aranda, Isidoro|||0000-0001-6302-1034
Background: Immunotherapy-based treatments have demonstrated high efficacy in patients with advanced and locally advanced non-small-cell lung cancer (NSCLC). BRAF mutations affect a small but significant fraction of NSCLC. The efficacy of these therapies in this subgroup of patients is unknown. Materials and methods: Plasma and tissue samples from 116 resectable stage IIIA/B NSCLC patients, included in NADIM and NADIM II clinical trials (NADIM cohort), and from a prospective academic cohort with 84 stage IV NSCLC patients (BLI-O cohort), were analyzed by next-generation sequencing. Results: The p.G464E, p.G466R, p.G466V, p.G469V, p.L597Q, p.T599I, p.V600E (n = 2) BRAF mutations, were identified in four (3.45 %) samples from the NADIM cohort, all of which were cases treated with neoadjuvant chemoimmunotherapy (CH-IO), and four (4.76 %) samples from the BLI-O cohort, corresponding to cases treated with first-line immunotherapy (n = 2) or CH-IO (n = 2). All these patients were alive and had no evidence of disease at data cut-off. Conversely, patients with BRAF wild-type (wt) tumors in the BLI-O cohort had a median progression-free survival (PFS) of 5.49 months and a median overall survival (OS) of 12.00 months (P-LogRank = 0.013 and 0.046, respectively). Likewise, PFS and OS probabilities at 36 months were 60.5 % and 76.1 % for patients with BRAF-wt tumors in the NADIM cohort. The pathological complete response (pCR) rate after neoadjuvant CH-IO in patients with BRAF-positive tumors (n = 4) was 100 %, whereas the pCR rate in the BRAF-wt population was 44.3 % (RR: 2.26; 95 % CI: 1.78-2.85; P < 0.001). Conclusion: BRAF mutations may be a good prognostic factor for advanced and locally advanced NSCLC patients undergoing immunotherapy-based treatments.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Optimized size exclusion chromatography demonstrates that extracellular vesicles are the key RNA carriers of ALK translocations in non-small cell lung cancer cell line secretome and patient plasma

  • Benayas, Beatriz
  • Sánchez-Herrero, Estela
  • Robado de Lope, Lucía
  • Morales, Joaquín
  • López-Martín, Soraya
  • Provencio, Mariano
  • Valés-Gómez, Mar
  • Romero, Atocha
  • Yáñez-Mó, María
Aim: Identification of ALK fusions in non-small cell lung cancer (NSCLC) is key to determining eligibility for treatment with ALK inhibitors that markedly improve patients' quality of life and survival outcomes. Circulating RNA, associated with various carriers including extracellular vesicles (EVs), lipoproteins (LPPs), or protein complexes, presents a viable target for the identification of ALK fusions by liquid biopsy. Our aim was to characterize the specific carrier of ALK fusion RNA, a crucial step in the development of diagnostic methods for clinical use. Methods: We employed optimized size-exclusion chromatography (SEC) to separate EVs, LPPs, and protein-enriched fractions from ALK-positive NSCLC cell lines and from pools of plasma obtained from NSCLC patients with ALK translocations. We optimized RNA fusion transcript detection using digital PCR (dPCR). Results: Protein analyses confirmed the successful resolution of EVs, LPPs, and protein fractions by optimized SEC. Our dPCR results indicated that ALK fusions were more prevalent in tetraspanin-enriched SEC fractions from NSCLC cell lines, suggesting that EVs serve as the primary carrier for ALK fusion RNA. After optimization for larger volumes of samples of the RNA isolation protocol, we could also demonstrate that ALK fusion transcripts were found exclusively in EVs from patient plasma. Of note, the circulating number of copies of the transcript was below 5 copies/mL. Discussion: Our findings underscore the potential of EV-associated RNA as a promising source for detecting ALK fusion variants in plasma samples from NSCLC patients, offering a non-invasive diagnostic approach with significant clinical implications., This work was supported by grants PID2020- 119627GB-I00 (MY-M) PID2021-123795OB-I00 (MVG) from the Spanish Ministry of Science and Innovation [Ministerio de Ciencia e Innovación (MCIN)/Agencia Estatal de Investigación (AEI) (MCIN/AEI/ 10.13039/501100011033) and the European Regional Development Fund (ERDF)-A way of making Europe] and by Instituto de Salud Carlos III through the projects (PI21/01500, DTS21/00124, and DTS21/00134) (co-funded by the European Regional Development Fund/European Social Fund). Benayas B was supported by a graduate industrial contract (IND2019_BMD-17100) and Morales J by the (PEJ-2023-AI_SAL-GL-26725) contract, both from Comunidad Autónoma de Madrid. Robado de Lope L was supported by a Juan de la Cierva fellowship (JDC2022-049091-I)., Peer reviewed